ARTICLE SUMMARY:
Cardinal Health has agreed to purchase J&J’s Cordis cardiology and endovascular device business, a move that offers substantial long-term benefits for both companies, but also raises some interesting questions about the future of the device industry and what it will take for companies to compete effectively in a shifting, increasingly cost-conscious marketplace.
Earlier this month, Johnson & Johnson announced that Cardinal Health Inc. signed a binding agreement to purchase J&J’s Cordis Corp. interventional cardiology and endovascular device business for $1.944 billion in cash (about $1.6 billion net of tax benefits).
